Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Kogenate FS in Severe Hemophilia A
NCT00245297Phase 2Completed
- Sponsor
- Recoly
- Start
- Oct 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of octocog alfa in hemophilia A (4 arms), sponsored by Recoly. Primary endpoint: Length of bleeding free periods up to 4 months. Started Oct 2005; status: completed.
02
Drugs
octocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT00245297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00245297.